Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Other Accumulated Expenses (2021 - 2024)

Historic Other Accumulated Expenses for Lyra Therapeutics (LYRA) over the last 4 years, with Q4 2024 value amounting to $475000.0.

  • Lyra Therapeutics' Other Accumulated Expenses fell 6141.35% to $475000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $475000.0, marking a year-over-year decrease of 6141.35%. This contributed to the annual value of $475000.0 for FY2024, which is 6141.35% down from last year.
  • According to the latest figures from Q4 2024, Lyra Therapeutics' Other Accumulated Expenses is $475000.0, which was down 6141.35% from $1.2 million recorded in Q4 2023.
  • In the past 5 years, Lyra Therapeutics' Other Accumulated Expenses registered a high of $1.2 million during Q4 2023, and its lowest value of $40000.0 during Q1 2022.
  • In the last 4 years, Lyra Therapeutics' Other Accumulated Expenses had a median value of $214500.0 in 2021 and averaged $371100.0.
  • Per our database at Business Quant, Lyra Therapeutics' Other Accumulated Expenses surged by 13000.0% in 2022 and then plummeted by 6141.35% in 2024.
  • Quarter analysis of 4 years shows Lyra Therapeutics' Other Accumulated Expenses stood at $633000.0 in 2021, then grew by 4.11% to $659000.0 in 2022, then soared by 86.8% to $1.2 million in 2023, then tumbled by 61.41% to $475000.0 in 2024.
  • Its last three reported values are $475000.0 in Q4 2024, $1.2 million for Q4 2023, and $659000.0 during Q4 2022.